Pfizer Inc. $PFE Stock Bought by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 276.7% in the third quarter, HoldingsChannel reports. The fund owned 101,626 shares of the biopharmaceutical company’s stock after purchasing an additional 74,645 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Pfizer were worth $2,898,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. State Street Corp lifted its holdings in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after purchasing an additional 5,364,929 shares during the last quarter. Bank of America Corp DE acquired a new stake in shares of Pfizer in the 2nd quarter worth $1,049,602,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Pfizer by 0.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after purchasing an additional 293,029 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Pfizer Trading Up 1.8%

Shares of Pfizer stock opened at $30.48 on Friday. The firm’s 50 day simple moving average is $28.55 and its two-hundred day simple moving average is $26.79. The firm has a market capitalization of $173.73 billion, a price-to-earnings ratio of 40.11, a PEG ratio of 2.03 and a beta of 0.32. Pfizer Inc. has a 12-month low of $23.62 and a 12-month high of $30.67. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm posted $0.78 earnings per share. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s dividend payout ratio is presently 226.32%.

Analysts Set New Price Targets

Several research analysts recently weighed in on PFE shares. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Scotiabank increased their price target on Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald increased their price target on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, October 13th. Finally, BMO Capital Markets dropped their price target on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.65.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.